# Bios Life raises $25M for AI-powered cancer surveillance platform Continuous monitoring system set to launch in late 2026 with Tempus data partnership - **Source:** [The Next Web](https://brifing.si/source/afe24b20-b275-4c19-b9a6-8bb3c8babae7) - **Published:** 2026-08-11 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/a2e35d98-9a3c-45cd-b385-172d44d0b6cd ## Revolutionizing cancer monitoring BioNTech alumni-founded Bios Life secured $25M to transform cancer screening from one-time tests to continuous AI surveillance. Their platform, powered by Tempus' data partnership, creates continuously updated 'digital twins' of patients' biology. Targeting 40M American cancer survivors and high-risk individuals, the system aims to replace fragmented care with lifetime monitoring. ## Investor backing and timeline The seed round was led by Redmile, Vsquared Ventures and Kindred Capital, with participation from US-European health-tech investors. The virtual-first platform, staffed by licensed clinicians and partnered with cancer centers, is slated for launch in late 2026. A waitlist is already open for the Boston-based company's service. ## Core technology Bios Life holds commercial rights to BioNTech-InstaDeep's 'Nucleotide Transformer' genomics model, one of the field's most cited. This single-nucleotide-resolution AI analyzes breast cancer scans more accurately than biopsies in some studies. Tempus' de-identified oncology datasets train the predictive algorithms, forming the system's backbone. ## Clinical need and data strategy Duke's Dr. Kevin Oeffinger calls cancer screening a 'standstill' for decades. Bios Life integrates Tempus-owned Ambry Genetics' hereditary cancer tests into its platform, combining genetic risk with lifestyle/clinical data. This multilayered approach could set new standards in risk assessment for 40% of people who will face cancer diagnoses. ## Founders' pedigree CEO Ryan Richardson previously served as BioNTech's CSO and chaired its AI arm InstaDeep. The team comprises BioNTech-InstaDeep veterans who rode the mRNA and genomics-AI wave. Bios Life follows the trend of heavyweight operators leaving big firms to build data-driven medicine startups in this hot health-AI moment. ## Early detection imperative Over 40% of people receive cancer diagnoses, often at late stages (III-IV) when outcomes worsen. Bios Life's tech, starting with breast cancer detection, aims to shift this paradigm. Their digital twin concept could transform disjointed screening into proactive monitoring, potentially saving lives through earlier interventions. ## Risks and challenges The unlaunched platform faces clinical validation requirements for its AI predictions. Continuous monitoring risks false alarms, over-screening, and patient anxiety—hazards the field is still learning to manage. With health AI hype often outpacing results, Bios Life must demonstrate real clinical utility beyond technological promise. ## Industry impact While Bios Life has team pedigree, Tempus data, and funding, its true test lies in proving lifelong surveillance benefits outweigh risks. Success could catalyze a global shift from reactive to proactive cancer care. Pre-launch clinical studies through 2026 will determine whether this $25M bet delivers on its ambitious vision. ## Sources covering this story - https://thenextweb.com/news/bios-life-25m-ai-cancer-surveillance-tempus — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._